We are a world leading clinical stage biotech company developing potential first-in-class antigen-specific immunotherapeutics targeting the immunological basis of autoimmune diseases.

We use our novel, proprietary discovery platform to select and develop highly specific peptide-based therapies, known as “apitopes®”, which restore the natural balance of the immune system. This mechanism of action avoids global immune suppression and has the broad potential to treat a wide variety of autoimmune diseases.

We have developed a robust pipeline of innovative, potential first-in-class product candidates in clinical and pre-clinical development, thereby focussing on autoimmune diseases with significant unmet medical need.